BioSpace News Archive

Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 1,923,077 shares of its common stock, at a public offering price of $65.00 per share.

LGC, Biosearch Technologies today announces the release of a new set of ValuPanel™ Reagents to help the efforts of public health laboratories to detect SARS-CoV-2, influenza A, and influenza B.

Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that the National Medical Products Administration of China has approved the supplemental New Drug Application of TYVYT® in combination with pemetrexed and platinum chemotherapy as first-line therapy for people with nonsquamous non-small cell lung cancer.